| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A800 | U.California patent anti-CDCP1 Featured |
|
|
| A809 | CM-24 Featured |
|
|
| A801 | Stem Centrx patent anti-Cadherin-1 Featured |
|
|
| A802 | RG-6125 Featured |
|
|
| A803 | 10C12 Featured |
|
|
| A804 | Anti-CDH17/Cadherin-17 Antibody (PTA001_A4) Featured |
|
|
| A805 | PF-03732010 Featured |
|
|
| A806 | DS-6000A Featured |
|
|
| A807 | HKT288 Featured |
|
|
| A808 | Actoxumab Featured | Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB. |
|
| A810 | Chaim Sheba Med. Cntr. patent anti-CEACAM1 Featured |
|
|
| A811 | Tusamitamab Featured | Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). |
|
| A812 | Labetuzumab Featured | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. |
|
| A813 | Tinurilimab Featured | Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. |
|
| A814 | NEO-201 Featured |
|
|
| A815 | Brown U. patent anti-CHI3L1 Featured |
|
|
| A816 | Academia Sinica patent anti-Clathrin Heavy Chain Featured |
|
|
| DC67161 | MPEG-2000-DPPE Na Featured |
|
|
| DC67162 | (S)-GSK-3685032 Featured | (S)-GSK-3685032 is the isomer of GSK-3685032 (HY-139664), and can be used as an experimental control. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. |
|
| DC67163 | 1-Piperazinecarboxylic acid, 4-[6-(methoxycarbonyl)-3-pyridinyl]-, 1,1-dimethylethyl ester Featured |
|
|
| DC67164 | WAY-204688 Featured | WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells. |
|
| DC67165 | Benzamide, 2-[(4-hydroxyphenyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]- Featured |
|
|
| DC67166 | 8-((1R,2R)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one Featured |
|
|
| DC67167 | Antifungal agent 35 Featured | Antifungal agent 35 (compound 24) is a potent antifungal agent. Antifungal agent 35 is a potent enhancer of antifungal activity of Fluconazole against C. albicans. |
|
| DC67168 | YAP/TAZ inhibitor-2 Featured | YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity. |
|
| DC67169 | 2-Naphthalenecarboxylic acid, 6-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]-, methyl ester Featured |
|
|
| DC67170 | 1-Hydroxy-3,6-bis[2-hydroxy-3-[methyl(phenylmethyl)amino]propoxy]-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one Featured |
|
|
| DC67171 | Macamide B Featured | Macamide B (N-Benzylhexadecanamide; Macamide 1) is a macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH). |
|
| DC67172 | (3R)-Benazepril Hydrochloride Featured |
|
|
| DC67173 | Diacetic Aceclofenac Featured |
|
